A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers

Trial Profile

A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Ruxolitinib deuterated (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 04 Mar 2017 Results of this trial were presented in a poster session at the American Academy of Dermatology Annual Meeting, according to a Concert Phamaceuticals media release.
    • 04 Mar 2017 Results published in a Concert Phamaceuticals media release.
    • 14 Dec 2016 According to a Concert Phamaceuticals media release, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top